10-Q: Alterola Biotech Reports Increased Operating Expenses and Net Loss in Q2 2024 Amidst Strategic Restructuring

Alterola Biotech's Q2 2024 financial results reveal a significant increase in operating expenses and net loss as the company continues its strategic shift towards cannabinoid-based pharmaceuticals and prepares for a potential merger.

Summary

• Alterola Biotech reported a net loss of $799,193 for the three months ended September 30, 2024, compared to a net loss of $123,157 for the same period in 2023.
• Operating expenses for the quarter increased to $477,231, up from $123,157 in the prior year, driven by higher consulting, accounting, and legal fees.
• The company's six-month net loss totaled $1,453,940, compared to $854,887 in the same period of 2023.
• Operating expenses for the six months ended September 30, 2024, were $1,160,053, compared to $716,724 for the same period in 2023.
• As of September 30, 2024, Alterola had a working capital deficit of $2,468,290 and a total accumulated deficit of $13,673,734.
• The company has not generated any revenue since inception and anticipates recurring losses as it develops its pharmaceutical products.
• Alterola is dependent on securing additional financing to continue operations and implement its business plan.
• The company is pursuing a merger with Chain Bridge I (NASDAQ: CBRG) through its subsidiary Phytanix Bio, which is expected to close in the fourth quarter of 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a substantial working capital deficit, and material weaknesses in internal controls, which are major concerns for investors. While the company is pursuing a merger and has secured some financing, the overall financial health and going concern risks overshadow these positives.

Positives

• The company is actively pursuing a merger with Chain Bridge I, which could provide access to public markets and additional capital.
• Alterola has secured financing through the issuance of promissory notes and warrants, providing short-term capital.
• The company is focused on developing cannabinoid-based pharmaceuticals, a growing market with significant potential.
• Alterola has acquired intellectual property and technology to support its research and development efforts.

Negatives

• The company has incurred significant losses and has a substantial working capital deficit.
• Operating expenses have increased significantly, primarily due to consulting, accounting, and legal fees.
• Alterola has not generated any revenue since its inception and is dependent on external financing.
• The company has identified material weaknesses in its internal controls over financial reporting.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• There is no guarantee that the merger with Chain Bridge I will be completed successfully.
• The company faces significant competition in the pharmaceutical industry.
• The development of pharmaceutical products is subject to regulatory risks and uncertainties.
• The company has identified material weaknesses in its internal controls over financial reporting, which could lead to misstatements in its financial statements.

Future Outlook

The company expects to incur further losses as it develops its business and is dependent on securing additional financing. Management plans to continue financing operations through private or public placement of debt and/or equity securities and the reduction of expenditures. The company anticipates the merger with Chain Bridge I to close in the fourth quarter of 2024.

Management Comments

• Management believes in harnessing the therapeutic potential of cannabinoids and cannabinoid-like compounds.
• Management plans to continue to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures.
• Management has extensive experience, know-how and connections in the cannabinoid medicines sector.

Industry Context

The company is operating in the rapidly evolving cannabinoid-based pharmaceutical industry, which is characterized by significant research and development costs, regulatory hurdles, and competition. The company's focus on developing novel cannabinoid molecules and delivery systems aligns with the industry's trend towards innovative therapeutic approaches.

Comparison to Industry Standards

• The company's lack of revenue and significant losses are typical for early-stage biotech companies focused on drug development, such as Amylyx Pharmaceuticals (AMLX) and Cassava Sciences (SAVA), which also experience high R&D costs and net losses before commercialization.
• The company's reliance on external financing is common in the biotech industry, where companies often raise capital through equity or debt offerings, similar to companies like BioNTech (BNTX) and Moderna (MRNA) in their early stages.
• The company's focus on cannabinoid-based therapeutics places it in a competitive landscape with companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) and Canopy Growth (CGC), which have also invested heavily in this area.
• The company's merger with a SPAC (Chain Bridge I) is a common strategy for biotech companies seeking to access public markets, similar to the mergers of companies like 23andMe (ME) and Ginkgo Bioworks (DNA).
• The company's reported material weaknesses in internal controls are not uncommon for smaller, rapidly growing companies, but they need to be addressed to ensure financial reporting reliability, similar to issues faced by other companies during their growth phases.

Corporate Governance

Related Party Transactions

• An officer has provided office space as an arms length transaction with rental at commercial rates.
• A shareholder made advances to the Company to fund operating expenses in the amount of $49,014.
• The company had outstanding notes payable with a related party of $1,839,731.
• The company had outstanding convertible note payable with a related party of $313,669.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial losses and going concern issues.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and suppliers may be affected by the company's ability to continue operations.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to remediate material weaknesses in internal control over financial reporting.
• The company intends to secure additional financing to fund operations.
• The company is working towards the closing of the merger with Chain Bridge I, expected in the fourth quarter of 2024.
• The company will continue to develop its cannabinoid-based pharmaceutical products.

Key Dates

Keywords

cannabinoid, pharmaceutical, biotech, merger, Phytanix Bio, Chain Bridge I, operating expenses, net loss, financing, working capital, internal controls, promissory notes, warrants